HOUSTON – Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its request for Fast Track Designation for its drug,...
treatment News
Melbourne, Australia – Australian researchers have worked out how to fix a defect that causes lupus, and hope their world-first discovery will offer effective long-term treatment. Published in Nature Communications, the Monash University-led study found a way to reprogram the defective cells of lupus patients with protective molecules from healthy...
BALTIMORE — The 2009 monsoon season will soon arrive in the Asian territories and culicine mosquito populations are expected to increase. “These mosquitoes may carry the virus that causes Japanese Encephalitis (JE), which kills 10-15,000 people each year,” warned Fran Lessans, CEO of Passport Health, the largest provider of travel...
BRONX, NY—Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)—two related blood diseases that disproportionally strike older adults—are notoriously difficult to treat and associated with high relapse rates. Although new therapies have improved survival, treatment options remain limited, and the prognosis for the 50% of people who experience disease relapse remains...
ZUG, Switzerland, February 26, 2024 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced the successful outcome of its end-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA), as well as positive feedback from its interactions with the E.U....
Munich, Germany – MorphoSys is moving ahead with its investigational BET inhibitor pelabresib, a Phase III myelofibrosis drug candidate, even though it failed to meet one of two key endpoints in a recent trial. The biopharma’s decision to stick with pelabresib follows similarly mixed results for AbbVie’s myelofibrosis drug navitoclax...
New York, NY — Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way that ovarian cancer tumors manipulate their environment to resist immunotherapy and identified a drug target that could overcome that resistance. The study, published in the October 30 online issue of Cell [DOI: 10.1016/j.cell.2024.10.006],...
Twenty-four parliamentarians across party lines have approached Union health and family welfare minister Mansukh Mandaviya, underlining the need for sustainable funding support for certain diseases under the National Policy for Rare Diseases 2021.
Minimal residual disease (MRD) assessment can be used to guide treatment discontinuation in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), according to phase 2 results published in the Journal of Clinical Oncology. The phase 2 CAPTIVATE trial (ClinicalTrials.gov Identifier: NCT02910583) was designed to test MRD-guided treatment discontinuation after first-line ibrutinib plus...
London, UK – The research, published in Science Translational Medicine, found that messenger RNA (mRNA) could be used to correct a rare liver genetic disease known as argininosuccinic aciduria in a mouse model of the disease. Argininosuccinic aciduria is an inherited metabolic disorder that affects how the body breaks down...